FDA Grants Ibrutinib/Rituximab Priority Review for Waldenstrom Macroglobulinemia
Pharma & biotech2018-06-25
10 Views
The FDA has granted a priority review to a supplemental new drug application ibrutinib for use in combination with rituximab as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.
Source: OncLive
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
NIO Inc. (NYSE: NIO) Provides November 2020 Delivery Update
